Form 4: Amicus Therapeutics Director Michael Raab Granted Significant Equity Awards

Amicus Therapeutics, Inc. Director Michael Raab was granted 20,414 Restricted Stock Units and options to purchase 74,872 shares of common stock, effective June 5, 2025.

Summary

• Director Michael Raab of Amicus Therapeutics, Inc. received equity awards on June 5, 2025.
• He was granted 20,414 Restricted Stock Units (RSUs), which are equivalent to common stock shares and will vest in full on the one-year anniversary of the grant date (June 5, 2026).
• Additionally, he was granted stock options to purchase 74,872 shares of common stock at an exercise price of $5.96 per share.
• These stock options will vest 100% on the one-year anniversary of the grant date (June 5, 2026) and expire on June 5, 2035.
• Following these transactions, Michael Raab beneficially owns 115,857 shares of common stock directly and 74,872 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is a positive sign of aligning management interests with shareholders, but it does not contain new operational or financial performance information to significantly alter sentiment.

Positives

• The grant of RSUs and stock options to Director Michael Raab aligns his interests with long-term shareholder value, as the awards vest over time.
• The equity awards serve as an incentive for the director's continued commitment and performance.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance beyond the vesting and expiration dates of the granted equity.

Industry Context

This is a standard insider transaction filing (Form 4) reporting equity compensation for a director. It does not provide broader industry trends or competitive analysis. Such grants are common practice in the biotechnology and pharmaceutical sectors to incentivize leadership.

Comparison to Industry Standards

• The grant of equity awards (RSUs and stock options) to directors is a common compensation practice across the biotechnology and pharmaceutical industries, aligning director interests with shareholder value.
• The vesting schedule of one year for both RSUs and stock options is a typical short-to-medium term incentive structure, though longer vesting periods are also common for executive performance awards.
• The exercise price of $5.96 for the options would typically be the closing price of FOLD stock on the grant date, which is standard for incentive stock options.

Corporate Governance

Related Party Transactions

• The transaction involves an equity grant to a director, which is a related party transaction, but it is a standard compensation event rather than an unusual dealing.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on general employees is indicated.

Next Steps

• The Restricted Stock Units will vest on June 5, 2026.
• The Stock Options will vest and become exercisable on June 5, 2026.

Key Dates

Keywords

Amicus Therapeutics, FOLD, Michael Raab, Director, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Executive Compensation, Beneficial Ownership